Q-omics provides the consensus-scored ELOCP21 profile across patient tissues and cancer cell-line models. ELOCP21 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, ELOCP21 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, ELOCP21 RNA expression shows 15,735 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight DLBC, KIRC, and UVM as cancer lineages where ELOCP21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOCP21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOCP21 survival associations across molecular data types. ELOCP21 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOCP21 RNA expression–survival associations across cancer types. High ELOCP21 expression shows unfavorable associations in DLBC, COAD, ACC, MESO, KIRP and UCEC. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for ELOCP21 RNA expression.
This table summarizes ELOCP21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ELOCP21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOCP21 shows lower tumor expression in KIRC and KIRP and higher tumor expression in KICH, LUSC, LIHC and BLCA. The KIRC box plot shows higher ELOCP21 RNA expression in normal versus tumor tissue (log2 FC = −1.088, t-test p < 0.001).
This table shows molecular features associated with ELOCP21 in patient tissues and cancer cell lines. In patient samples, ELOCP21 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
